Risk of fractures and bone abnormalities in postmenopausal women with type 2 diabetes mellitus

Introduction

Type 2 diabetes mellitus (DM) is a pandemic metabolic disease with elevated morbidity and mortality. It is characterized by hyperglycemia secondary to peripheral insulin resistance with a variable degree of hyperinsulinemia and insulin secretion impairment. Hyperglycemia may have several adverse effects on bone metabolism especially in patients with poorly controlled diabetes. Glucose is the main energy source for osteoclasts and is able to dose-dependently enhance avian osteoclast activity in vitro (1). In addition, hyperglycemia leads to nonenzymatic glycosylation of various bone proteins, including type 1 collagen, which may impair bone quality (2).

The currently available data on bone metabolism and fracture risk in patients with DM are partly conflicting and inconclusive due to inhomogeneous study population and design. Patients with DM have various skeletal disorders, including osteopenia or osteoporosis, Charcot’s arthropathy and the diabetic foot syndrome (3). An increased prevalence of type 2 DM has been described in vitamin D-deficient individuals, and insulin synthesis and secretion have been shown to be impaired in beta cells from vitamin D-deficient animals (4-6). Glucose tolerance is restored when vitamin D levels return to normal (7). In type 1 DM an increased fracture risk has been shown and is associated to a decreased bone mineral density (8-10). The demineralization process involves especially the trabecular bone, and the decrease in bone mass is more significant in the first five years after the onset of the disease (11). On the contrary, in type 2 DM, the most of studies highlight normal or elevated (11-16) bone mineral density, and these results are surprising in consideration of the increased fracture risk which occurs also in type 2 DM patients (17-19). The reasons for this discrepancy are not fully understood.

In the general population, it has been demonstrated that bone mineral density and risk of fractures is inversely correlated to the body mass index (BMI) (20). Since the BMI is higher in type 2 than in type 1 DM, this may represent a possible explanation for the normal bone mineral density seen in type 2 DM patients. As a consequence, it is likely that type 2 DM subjects are characterized by an altered bone quality regardless from the bone mineral density.

The aim of this study was to evaluate which factors may explain the risk of fractures in a homogeneous population of postmenopausal women with type 2 DM.

Patients & Methods

Patients

A total of 27 consecutive women with type 2 DM referred to the Unity of Diabetology and Endocrinology, Hospital of Aosta, between March and October 2009, were enrolled in this study. The study protocol was approved by the local ethics committee institutional board and was carried out in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki as revised in 2000. This study included women who were diagnosed with type 2 DM according to American Diabetes Association (ADA).
Risk of fractures and bone abnormalities in postmenopausal women with type 2 diabetes mellitus

criteria (21). The exclusion criteria were patients affected with diseases associated with bone impairment such as Cushing’s syndrome, hypothyroidism, hyperthyroidism, prolactinomas, hyperparathyroidism, renal failure, malabsorption, chronic alcohol intake or heavy smoking, and medications that might affect bone and mineral metabolism. After the exclusion of three patients with hyperthyroidism and three patients with primary hyperparathyroidism, 21 patients, aged 43-70 years (mean 63 ± 10 SD years) were studied. The duration of diabetes varied 1-30 years. The anti-DM treatment was diet in 1 patient, hypoglycemic drugs in 15 patients, insulin in 4 patients, hypoglycemic drugs plus insulin in 1 patient. All patients were postmenopausal subjects and were not taking any hormone replacement therapy. All patients underwent a clinical, biochemical and bone mineral density examination.

The clinical, biochemical and bone mineral density characteristics of the 21 patients are shown in Table 1.

Methods

Clinical assessment

Height, weight, BMI, systolic blood pressure (SBP), diastolic blood pressure (DBP) were evaluated by standard methods. BMI was measured as the ratio between the weight and the square of the height. A BMI between 25 and 30 Kg/m² was considered the index of obesity (22). Blood pressure was measured in the right arm, with the subjects in a relaxed sitting position. The average of 6 measurements (3 taken by each of 2 examiners) with a mercury sphygmomanometer was used. Hypertension was diagnosed when DBP values were ≥ 90 mmHg and SBP values were ≥ 130 mmHg in line with Adult Treatment Panel III (23).

Biochemical assessment

Glycemia, glycated hemoglobin (HbA₁c), total cholesterol, HDL cholesterol, triglycerides, uremia, creatinine, calcium, phosphorus, albumin, total alkaline phosphatase (ALP) were determined on serum samples at fasting by automated techniques (Roche Modular System). Intact parathyroid hormone (PTH) and paraprotein were measured by electrochemiluminescence immunoassay concentration and with the Claus method, respectively. Serum levels of 25-hydroxyvitamin D (25-OHD) were measured with direct radioimmunoassay. Hypovitaminosis D deficiency was defined as a serum concentration of 25-OHD between 20-30 ng/ml and hypovitaminosis D deficiency was defined as a serum concentration of 25-OHD below 20 ng/ml (24,25). The urinary albumin excretion rate was measured from a single 24-h urine collection. A urinary albumin excretion rate of 30 to 300 µg per min was defined as microalbuminuria, a rate greater than 300 µg per min was defined as macroalbuminuria. Urinary calcium, phosphorus and creatinine were also measured on 24-h urine samples.

Instrumental investigation

Bone mineral density was measured by dual-energy x-ray absorptiometry technique (DXA) at the spine and femoral neck. DXA measures areal BMD in g/cm² by using ionizing radiation with photon beams of two different energy levels, T-score, the SD from the mean value obtained in 30 year old normal subjects, and Z-score, the SD from the mean value obtained in subjects of the same age and sex. A T-score -1 SD or grater was considered normal, between -1 and -2.5 SD was consistent with osteopenia, lower than -2.5 SD was consistent with osteoporosis and lower than -2.5 SD or less with a fragility fracture was consistent with severe osteoporosis (26, 27). A lumbar spine radiography was performed in antero-posterior and latero-lateral in all patients to assess the existence of vertebral fractures.

Table 1 - Clinical, biochemical and instrumental parameters.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mean±SD</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs)</td>
<td>63.4±13.8</td>
<td>43 – 70</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>132.1±13.8</td>
<td>100 – 160</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>78±8.8</td>
<td>70 – 100</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>29.3±4.7</td>
<td>21 – 36.7</td>
</tr>
<tr>
<td>Disease duration (yrs)</td>
<td>8±6.5</td>
<td>1 – 30</td>
</tr>
<tr>
<td>Serum fasting glucose (mg/dl)</td>
<td>162±28.8</td>
<td>125 – 227</td>
</tr>
<tr>
<td>Glycated hemoglobin (%)</td>
<td>7.7±1</td>
<td>6 – 10.9</td>
</tr>
<tr>
<td>Total cholesterol (mg/dl)</td>
<td>214±35.2</td>
<td>127 – 346</td>
</tr>
<tr>
<td>HDL-cholesterol (mg/dl)</td>
<td>57±17.7</td>
<td>31 – 87</td>
</tr>
<tr>
<td>Triglycerides (mg/dl)</td>
<td>171±157.3</td>
<td>71 – 600</td>
</tr>
<tr>
<td>Uremia (mg/dl)</td>
<td>4.7±1.1</td>
<td>2.9 – 6.8</td>
</tr>
<tr>
<td>Serum albumin (g/L)</td>
<td>42.7±1.7</td>
<td>38 – 48.7</td>
</tr>
<tr>
<td>Serum creatinine (mg/dl)</td>
<td>0.79±0.1</td>
<td>0.5 – 0.93</td>
</tr>
<tr>
<td>Creatinine clearance (ml/min)</td>
<td>97.2±20.9</td>
<td>68 – 142</td>
</tr>
<tr>
<td>Microalbuminuria (µg/min)</td>
<td>26.8±26</td>
<td>2.3 – 100</td>
</tr>
<tr>
<td>25-hydroxyvitamin D (ng/ml)</td>
<td>18±6.4</td>
<td>7.8 – 32.4</td>
</tr>
<tr>
<td>Total alkaline phosphatase (U/L)</td>
<td>184±45.8</td>
<td>124 – 252</td>
</tr>
<tr>
<td>Parathyroid hormone (pg/ml)</td>
<td>61.6±29.6</td>
<td>18 – 154</td>
</tr>
<tr>
<td>Serum calcium (mg/dl)</td>
<td>9.6±0.4</td>
<td>8.7 – 10.2</td>
</tr>
<tr>
<td>Serum phosphorus (mg/dl)</td>
<td>3.4±0.5</td>
<td>2.3 – 4.1</td>
</tr>
<tr>
<td>Urinary calcium (mg/24-h)</td>
<td>136.9±95.2</td>
<td>54 – 420</td>
</tr>
<tr>
<td>Urinary phosphorus (mg/24h)</td>
<td>635.4±315.1</td>
<td>320 – 1120</td>
</tr>
<tr>
<td>(Lumbar spine) T-score</td>
<td>-1.1±1.1</td>
<td>0.6 – 2.8</td>
</tr>
<tr>
<td>(Lumbar spine) Z-score</td>
<td>0.1±1.1</td>
<td>2.5 – 2.9</td>
</tr>
<tr>
<td>(Femoral neck) T-score</td>
<td>-0.8±1.0</td>
<td>0.8 – 2.6</td>
</tr>
<tr>
<td>(Femoral neck) Z-score</td>
<td>0.1±0.9</td>
<td>1.5 – 1.8</td>
</tr>
</tbody>
</table>

Statistical Analysis

The statistical analysis was performed by SPSS for Windows version 10 (SPSS, Inc., Chicago, IL). Data were expressed as means±SD. The linear regression analysis by calculating the Pearson’s coefficient was used to study the correlation between numerical data and the logistic regression analysis was used to study the correlation between numerical data and risk of fractures. The p values were given for these analyses. The significance was set at 5%.

Results

Twenty of 21 subjects showed low levels of 25-OHD (mean 18±6.4 ng/ml). In particular 14 subjects (67%) showed a deficit of 25-OHD, and 6 subjects (28%) showed insufficient 25-OHD levels, only 1 patient (5%) had 25-OHD in the normal range. PTH levels were at the higher limits of the normal range and were not associated with serum calcium levels increased (Table 1). The percentage of patients with normocalcaemic hyperparathyroidism was 28%. At the MOC DXA examination, T-score revealed a condition of osteopenia at the lumbar spine while the Z-score was in accordance with age of patients both at lumbar and femoral neck level (Table 1). At the radiological assessment, 24% of patients showed one or more vertebral fractures (1 fracture was found in 15% and 2 or more fractures in 9%), (Figure 1). There was a direct correlation between the presence of fractures and the PTH serum levels (p<0.05), while an inverse correlation was observed between the presence of fractures and vitamin D levels (p<0.05). A mild but not significant direct correlation was between fractures and both serum glucose levels (p=0.06).
Clinical Cases in Mineral and Bone Metabolism 2010; 7(2): 126-129

Insufficiency. This condition of hypovitaminosis D was likely retrospective, and 28% of them had a 25-OHD deficiency as values below 20 ng/ml (24,25). In this study, 95% of the population met the normal value of serum 25-OHD concentrations should be revaluated (33-36). For these reasons, in this study we defined 25-OHD insufficiency as values between 20-30 ng/ml and 25-OHD deficiency as values below 20 ng/ml (24,25). In this study, 95% of patients showed low 25-OHD levels; in particular 67% of patients had a 25-OHD deficiency and 28% of them had a 25-OHD insufficiency. This condition of hypovitaminosis D was likely responsible for a mild normocalcaemic hyperparathyroidism found in the DM patients under evaluation in this study. Vitamin D stimulates insulin secretion by pancreatic beta cells but inhibits PTH synthesis (37).

Type 2 DM has been also associated with an increased risk of fractures at any skeletal site (9,10,17,19,38). Nicodemus et al. reported a higher risk of hip fractures in postmenopausal women with type 2 DM than in women without diabetes. In addition, a longer duration of diabetes and the use of insulin or oral diabetes medications in women with type 2 DM were associated with a higher risk of hip fractures (9). The same results were observed by Schwartz et al. (17), Ottenbacher et al. (19), Vestergaard et al. (38) and Bords et al. (39). These authors have found vertebral and non-vertebral fractures in patients with type 2 DM. The Rotterdam study, conducted on 792 elderly patients with type 2 DM (483 women and 309 men, mean age 74 years) confirmed an increased fracture risk despite a higher bone mineral density at femur neck and lumbar spine (40). In our study the prevalence of fractures, assessed at the lumbar spine, was 24% of patients and was associated with hyperparathyroidism.

In type 1 DM an increased fracture risk have been shown to occur in parallel with a reduced bone mass (9,10). On the contrary, in type 2 DM, severe but not all cross-sectional studies highlighted normal (11,12) or elevated (13-16) bone mass, and these results are surprising given the increased fracture risk associated with type 2 DM (17-19). The reasons for this discrepancy are not fully understood. A possible explanation is that type 2 diabetic patients have alterations in bone quality regardless from the bone mineral density.

In line with these data, in this study the bone mineral density was comparable between type 2 diabetic patients and normal subjects of comparable age as assessed by evaluating the Z-score. This finding was still more surprising if we consider that the study population included postmenopausal females. Therefore, the high rate of vertebral fractures (24%) we found could be attributed to a reduced bone quality. The mechanism resulting in bone alteration and high fracture risk in these patients may involve a deregulation in PTH secretion in a context of generalized vitamin D deficiency. Hypovitaminosis D could be a condition predisposing to fractures in all patients affected with type 2 DM, without correlation with glycemic control and duration of diabetes. The secondary impairment in PTH secretion could be the triggering factor resulting in a fracture event. In women with DM, the risk of fractures has been reported to increase with the fasting blood glucose levels (41). In line with this observation, we found a tendency toward a correlation between hyperglycemia as well as hypertension and occurrence of fractures, which needs to be confirmed in a larger series of patients.

In conclusion, the risk of vertebral fractures is increased in postmenopausal females with type 2 DM in spite of normal values of bone density. Hypovitaminosis D and consequent hyperparathyroidism are clear metabolic alterations which correlate with the high risk of fractures in these patients.

References


Risk of fractures and bone abnormalities in postmenopausal women with type 2 diabetes mellitus


